Amphastar has received permission from the Food and Drug Administration for iron sucrose injection, 50mg/2.5ml, 100mg/5ml and 200mg/10ml in single-dose vials, previously referred to as AMP-002. Iron ...

The Food and Drug Administration has given Viatris permission for iron sucrose injection, an intravenous iron replacement product used to treat iron deficiency anemia in adult and pediatric patients ...

All 3 strengths of iron sucrose injection are expected to be available “imminently”. The Food and Drug Administration (FDA) has approved the first generic version of Venofer ® (iron sucrose) Injection ...

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, ...

A total of 100 patients were identified as receiving at least one 300-mg dose of elemental iron i.v. as iron sucrose. Of these patients, 73 had NDDCKD; the remaining 27 patients had a CL cr of ≥60 ...

Viatris and Amphastar Pharmaceuticals both received Food and Drug Administration approval of generic iron sucrose injection products for the treatment of iron deficiency anemia in patients with ...

Iron repletion is a very common and necessary therapy for patients with NDDCKD. Oral iron supplementation is frequently not tolerated and sometimes inadequate to replete the body's iron stores. The ...